Regorafenib

Generic Name
Regorafenib
Brand Names
Stivarga
Drug Type
Small Molecule
Chemical Formula
C21H15ClF4N4O3
CAS Number
755037-03-7
Unique Ingredient Identifier
24T2A1DOYB
Background

Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

Indication

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...

Associated Conditions
Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
Associated Therapies
-
Clinical Trials
Related News

Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

First Posted Date
2020-09-01
Last Posted Date
2024-12-20
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Target Recruit Count
49
Registration Number
NCT04534218
Locations
🇫🇷

Hôpital Nord Franche-Comté, Montbéliard, France

🇫🇷

CHU de Besançon, Besançon, France

🇫🇷

Centre georges-François Leclerc, Dijon, France

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

First Posted Date
2020-06-16
Last Posted Date
2020-06-16
Lead Sponsor
Peking University
Target Recruit Count
268
Registration Number
NCT04431791
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

First Posted Date
2020-04-27
Last Posted Date
2024-08-05
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
39
Registration Number
NCT04362839
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

First Posted Date
2020-03-31
Last Posted Date
2024-06-14
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
25
Registration Number
NCT04327700
Locations
🇺🇸

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

First Posted Date
2019-12-16
Last Posted Date
2022-05-06
Lead Sponsor
CStone Pharmaceuticals
Target Recruit Count
19
Registration Number
NCT04200404
Locations
🇦🇺

Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia

Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)

Phase 1
Active, not recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Regorafenib
Drug: Nivolumab
First Posted Date
2019-11-20
Last Posted Date
2023-12-29
Lead Sponsor
Fundacion Clinic per a la Recerca Biomédica
Target Recruit Count
69
Registration Number
NCT04170556
Locations
🇪🇸

Hospital Vall d'Hebron, Barcelona, Spain

🇪🇸

Hospital Puerta de Hierro, Madrid, Spain

🇪🇸

Hospital Gregorio Marañon, Madrid, Spain

and more 4 locations

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

First Posted Date
2019-10-07
Last Posted Date
2024-02-07
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
22
Registration Number
NCT04117945
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 12 locations

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors.

First Posted Date
2019-10-04
Last Posted Date
2024-12-12
Lead Sponsor
Centre Leon Berard
Target Recruit Count
455
Registration Number
NCT04116541
Locations
🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

Institut Paoli Calmettes, Marseille, France

and more 5 locations

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Phase 2
Active, not recruiting
Conditions
Recurrent Glioblastoma
Interventions
Drug: Regorafenib
First Posted Date
2019-08-09
Last Posted Date
2024-12-05
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
14
Registration Number
NCT04051606
Locations
🇺🇸

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

First Posted Date
2019-07-05
Last Posted Date
2019-07-05
Lead Sponsor
China Medical University, China
Target Recruit Count
54
Registration Number
NCT04008511
Locations
🇨🇳

The First Hospital of China Medical University, Shenyang, Liaoning, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy